CODX

Co-Diagnostics, Inc. (CODX) SWOT Analysis Analysis (2026)

Invetso Score: 5.1/10 — Balanced · Last Updated: 2026-09-01

Monthly Update
Overall Score5.1 → 5.1
Change0

Strengths

Score: 4.3 (Moderate)

Co-Diagnostics’ liquidity and low leverage provide financial flexibility, while its active R&D pipeline positions it to address unmet needs in molecular diagnostics. However, these strengths are tempered by weak profitability and limited commercial traction.

Weaknesses

Score:

Co-Diagnostics faces high risk from persistent losses, weak revenue trends, and delayed market entry, which undermine its ability to scale and achieve sustainable profitability.

Opportunities

Score:

Co-Diagnostics is positioned to benefit from secular growth in molecular diagnostics and expansion into underserved markets, provided it can achieve regulatory clearance and commercial execution.

Threats

Score:

Co-Diagnostics faces high risk from regulatory hurdles, competitive pressures, and a challenging industry backdrop, all of which could impede its ability to scale and achieve profitability.

Overall Score

Score:

Co-Diagnostics exhibits moderate overall positioning, with strong liquidity and a promising R&D pipeline offset by persistent losses, weak revenue, and significant execution risks. Success depends on regulatory approvals, commercial traction, and the ability to capitalize on large addressable markets amid industry headwinds.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Co-Diagnostics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →

Invetso is not affiliated with or regulated by the U.S. Securities and Exchange Commission (SEC), the Financial Industry Regulatory Authority (FINRA), or any other financial regulatory authority. The analyses, scores and all the information provided by Invetso are strictly for informational purposes only and do not constitute financial advice, recommendations, or an offer to buy or sell any securities. Invetso is not a registered financial advisor, broker-dealer, or investment advisor, and it does not provide personalized investment, legal, or tax advice. The content provided on this website is not intended to serve as a substitute for professional advice. Users should conduct their own research and consult with a qualified financial advisor before making any investment decisions. All analysis, data, and information presented on this site are based on publicly available information and should be used at the user’s own risk. Invetso does not guarantee the accuracy, completeness, or timeliness of any information or data provided, nor does it endorse any specific securities, companies, or strategies. Any reliance you place on such information is strictly at your own risk. While we strive to provide accurate and up-to-date information, Invetso makes no warranties or representations regarding the completeness, accuracy, or reliability of any analyses or data on our platform, and any such information is subject to the terms and conditions of the Invetso Terms of Service. Our analyses are generated using AI technologies and AI-generated content may contain errors or inaccuracies. Use the information at your own risk. Our platform may contain links to third-party websites, for which we are not responsible for the content or accuracy of information. Invetso shall not be liable for any loss or damage arising from the use of our services. By using this website, you agree that Invetso is not responsible for any losses, damages, or financial outcomes that may result from your use of the information, tools, or resources provided. We recommend consulting with a licensed financial professional before making any investment decisions.

For more details, please refer to our Terms of Service and Privacy Policy.